GlassScriptPhysician profile
Scott J Kolbaba
NPI 1396776613
$10,611.32
in general payments reported to CMS, 2019-2025
48 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,594 · 2020: $1,539 · 2021: $1,559 · 2022: $1,543 · 2023: $1,536 · 2024: $1,529 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,360 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,360.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,070.29 | 2020-2025 | |
| Novo Nordisk INC | $1,034.96 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Kowa Pharmaceuticals America, INC. | $962.89 | 2019-2024 | Livalo, Seglentis |
| Astrazeneca Pharmaceuticals LP | $791.16 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $782.71 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $671.76 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Janssen Pharmaceuticals, INC | $658.15 | 2019-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $649.54 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $475.24 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $450.22 | 2019-2025 | |
| Amarin Pharma, INC. | $283.35 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $246.79 | 2022-2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $236.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $230.34 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $227.46 | 2020-2025 | Rexulti |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kolbaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.